Latest news with #GENFIT
Yahoo
5 days ago
- Business
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Non-alcoholic Steatohepatitis Biomarkers Market to Hit USD 9.1 Billion by 2032
The NASH Biomarkers Market Growth is driven by AI-Based Diagnostics, Biomarker Innovations and Non-Invasive Testing Technologies. Austin, June 12, 2025 (GLOBE NEWSWIRE) -- Non-alcoholic Steatohepatitis Biomarkers Market Size & Growth Analysis: According to SNS Insider, the Non-alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.14 billion in 2023 and is projected to reach USD 9.1 billion by 2032, growing at a CAGR of 25.9% during the forecast period 2024-2032. The increasing global prevalence of NASH, coupled with the rising adoption of non-invasive diagnostic tools, is significantly driving market growth. Additionally, advancements in biomarker research, propelled by AI-based diagnostic solutions and biomarker assay innovations, are fostering rapid market a Sample Report of Non-alcoholic Steatohepatitis Biomarkers Market@ Market Overview The increasing burden of NASH, a serious variant of non-alcoholic fatty liver disease (NAFLD), has propelled the need for effective diagnostic solutions. Invasive, costly, and complication-ridden traditional liver biopsies have given way to the increasing dependence on non-invasive biomarker-based diagnostic solutions. The increase in the prevalence of obesity, metabolic syndrome, and diabetes has also been a major driver in fueling the growing patient base of NASH, which has in turn led to increased biomarker demand. Industry leaders are concentrating on AI-based biomarker assays, proteomic and metabolomic innovation, and strategic partnerships to improve the detection and monitoring of NASH. Pharmaceutical organizations and CROs are leading the charge, using biomarker-driven strategies to enhance clinical trial effectiveness and streamline drug development. With regulatory approval backing innovative biomarker assays and increasing investment in biomarker studies, the market is expected to grow significantly over the forecast period. Major Players Analysis Listed in this Report are: GENFIT (NIS4™, Elafibranor) Gilead Sciences (Selonsertib, Cilofexor) AstraZeneca (Dapagliflozin, Epanova) Novartis AG (Tropifexor, LJN452) GE Healthcare (LiverMultiScan, FibroScan) Siemens Healthineers (ADVIA Centaur® CP Immunoassay System, Atellica® Solution) Bristol-Myers Squibb (Pegbelfermin, BMS-986036) Pfizer Inc. (PF-06865571, PF-05221304) Akero Therapeutics (Efruxifermin, AKR-001) 89bio (Pegozafermin, BIO89-100) Non-alcoholic Steatohepatitis Biomarkers Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.14 billion Market Size by 2032 US$ 9.1 billion CAGR CAGR of 25.9% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Type In 2023, the serum biomarkers segment led the market, accounting for 33% of total revenue. Serum biomarkers such as liver enzyme panels and inflammatory markers are much loved because of ease of usage, availability, and high precision of detection for NASH. In addition, demand for non-invasive methods for diagnosis and combination of AI-driven algorithms for detecting biomarkers is also promoting growth in this leading segment. The apoptosis biomarkers segment is expected to register the highest growth during the forecast period. Apoptosis biomarkers, including cytokeratin-18 (CK-18), are increasingly finding favor as they can offer insights into hepatocyte death and disease progression. Increased use of apoptosis biomarkers in clinical studies and their possible use in patient stratification for therapeutic interventions are some of the most important factors fueling their faster growth. By End-use The pharma and CRO industry segment held the highest market share of 39% in 2023. The segment's dominance is due to the growing dependence of pharmaceutical firms on biomarker-based approaches to drug discovery and clinical trials. NASH continues to be a prime area of interest for drug development, with several candidates in late-stage trials. CROs are instrumental in biomarker validation, expediting drug approvals, and increasing the effectiveness of clinical research, further increasing market share. The diagnostic laboratory segment is also expected to emerge as the growth leader over the next few years. Growing needs for sophisticated diagnostic solutions, and the increased choice for biomarker-based non-invasive tests, are driving growth in diagnostic laboratories focused on identifying NASH. Growing knowledge of the importance of early diagnosis by healthcare professionals and patients will propel this segment further. Non-alcoholic Steatohepatitis Biomarkers Market Segmentation By Type Serum Biomarkers Oxidative Stress Biomarkers Hepatic Fibrosis Biomarkers Apoptosis Biomarkers Others By End-use Pharma & CRO Industry Diagnostic Labs Hospitals Academic Research Institutes For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Regional Analysis North America dominated the NASH Biomarkers Market in 2023 with 40% of overall market share. The region is influenced by a well-developed healthcare infrastructure, significant research and development expenditure, and high NASH prevalence as a result of obesity and metabolic disorders. The presence of prominent pharmaceutical and diagnostic firms also fuels market growth. The Asia Pacific region is anticipated to have the highest growth during the forecast period. The increasing NAFLD and NASH burden, rising healthcare investments, and adoption of sophisticated biomarker-based diagnostic solutions are driving regional market growth. Increasing government initiatives and regulatory backing for non-invasive diagnostics further boost the market potential in this region. Recent Developments In September 2024, Siemens Healthineers released a next-generation NASH biomarker assay integrating multiple serum-based markers via AI algorithms to enhance diagnostic accuracy. The assay received FDA clearance for clinical use. In January 2025, AstraZeneca and Novo Nordisk collaborated to develop a biomarker platform combining genomic, proteomic, and metabolomic data to advance personalized NASH treatments. Statistical Insights and Trends Reporting The global prevalence of NASH was estimated at 5% to 6% of the adult population in 2023, with North America and Europe exhibiting the highest disease burden. North America accounted for 45% of total NASH biomarker-based diagnostic tests conducted, followed by Europe at 30%, with Asia-Pacific witnessing a rapid rise in test adoption. The number of biomarker assays performed globally for NASH is projected to grow 4x between 2020 and 2032, driven by increasing non-invasive diagnostic adoption. Global research funding for NASH biomarkers exceeded USD 2.5 billion in 2023, with major contributions from biotech firms and academic institutions. Government and private healthcare expenditures on NASH diagnostics and treatment surpassed USD 8 billion, reflecting growing investments in disease management. Buy a Single-User PDF of Non-alcoholic Steatohepatitis Biomarkers Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Non-alcoholic Steatohepatitis Biomarkers Market by Type 8. Non-alcoholic Steatohepatitis Biomarkers Market by End Use 9. Regional Analysis 10. Company Profiles 11. Use Cases and Best Practices 12. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen's Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC). This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen2, due upon pricing and reimbursement of Iqirvo® (elafibranor) in three major European markets3, and will allow us to continue progressing our pipeline in Acute On-Chronic Liver Failure (ACLF) and other life-threatening diseases. Milestone payments under the Licensing and Collaboration Agreement with Ipsen are not included in the scope of our royalty financing agreement with HCRx4. ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor5) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ GENFIT | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®2 3 Iqirvo® has already been granted pricing and reimbursement in the UK and in Germany4 Attachment GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders, financial analysts, analysts specializing in corporate social responsibility (CSR) issues, company employees and candidates wishing to join the Company, industrial and strategic partners, and public institutions. The 2025 report (fiscal year 2024) is available on GENFIT's website. Pascal Prigent, CEO of GENFIT, commented: 'Our approach to sustainable development is rooted in our corporate culture and has been integral to our strategy since the early days of GENFIT. The creation by the board of directors of a dedicated ESG Committee in 2021 has brought about a more structured process, with an annual roadmap, which translates into concrete actions, binding policies, and the monitoring of indicators linked to our priority issues. In 2025, while closely monitoring developments in reporting standards, we will continue to focus our efforts on what matters most for GENFIT, with a view to maximizing the positive impact of our actions, managing risks, and seizing opportunities. Building sustainably, investing in diverse teams, and operating with transparency strengthens trust with patients, regulators and investors, and we believe that GENFIT has demonstrated how ESG helps us progress towards our goals.' In 2024, GENFIT remained steadfast in its commitment to social and environmental responsibility and strengthened its momentum toward continuous improvement. The roadmap approved at the beginning of the year by the ESG Committee was implemented in accordance with the established objectives. The progress made reflects the collective involvement of all teams, departments, and levels of the organization. Developments in 2024 included a significant increase in engagement with and for patients through awareness initiatives, accelerated production of educational content on ACLF involving a wide range of international experts in the field, a comprehensive assessment of gender equality in the workplace, and, of course, the pursuit of numerous initiatives launched in the past. GENFIT has been monitoring regulatory developments and has prepared a progressive compliance plan for non-financial reporting under the CSRD framework, until the Omnibus Directive published at the beginning of 2025 led to the suspension of our transition plan to the ESRS standards associated with this directive1. This regulatory development does not, however, call into question our desire to move closer to European standards, as part of a voluntary approach tailored to our corporate profile. Our 2025 sustainability roadmap will be a continuation of the 2024 roadmap, and of what has been done in previous years. We'll be capitalizing on the experience we've gained and building on the feedback we've received to consolidate our commitment. Caroline Bendavid at HOMA Capital, commented: 'At HOMA Capital, we are particularly sensitive to the social issues of the companies in which we invest. We therefore closely follow GENFIT's initiatives in this area, and appreciate its commitment to the quality of life and working conditions of its employees. Its breast cancer prevention campaign, for example, is a concrete example of how simple actions can be implemented to prevent risks, make it easier for employees to take action and, indirectly, contribute to the dynamics of the organization. More generally, we find GENFIT's creative approach to meeting all the challenges associated with Corporate Social Responsibility to be very interesting.' Jon Potter, ACLF transplant patientdeclaredI'm very pleased to see GENFIT progressing with its clinical trials in ACLF, a severe liver syndrome, with the aim of developing a treatment that can truly improve patients' lives. Joining GENFIT's ACLF Patient Advocacy Council was an important step for me, as it represents real hope for all those fighting the disease. This hope goes beyond the patients themselves: it also involves their families, loved ones and friends. I feel I share a genuine common desire with GENFIT to move things forward in a positive way.' ABOUT OUR CSR COMMITMENT Our commitment is driven, above all, from our determination to act as a socially responsible company. As a biopharmaceutical company, this commitment goes beyond our core activity whose purpose it is to respond to the societal need of developing innovative, effective and safe therapeutic solutions for patients suffering from rare and severe liver diseases with a high unmet medical need. This is aligned with the third Sustainable Development Goal of the United Nations. GENFIT recognizes that there is a correlation between its long-term financial performance and its extra-financial performance in that the societal impact of its research and development programs, as well as its rigorous governance practices (particularly in relation to the demands of the relevant health authorities and financial market regulators), the social impact of its activity, and its low environmental footprint, could create meaningful long-term value for patients, healthcare systems, employees and shareholders, and assure the Company's growth and long-term future. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor2) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: + 33 3 20 16 40 00 | investors@ GENFIT | Press relationsStephanie BOYER | Tel : + 33 3 20 16 40 00 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Companies subject to the European Corporate Sustainability Reporting Directive have to report according to European Sustainability Reporting Standards (ESRS). For more information, visit the European Commission website2 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
Associated Press
10-02-2025
- Business
- Associated Press
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternatively to pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEs Both proposals are subject to approval of the royalty financing by the 2025 OCEANEs bondholders at the upcoming bondholders meeting and closing of the royalty financing Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holders of 2025 OCEANEs still outstanding after cancellation of repurchased 2025 OCEANEs. Context On January 30, 2025, GENFIT announced that it has entered into a non-dilutive capped royalty financing agreement (the 'Royalty Financing') with HealthCare Royalty (HCRx) for up to €185 million. This transaction significantly extends GENFIT's cash runway, including after the repayment of its bonds convertible into new shares and/or exchangeable into existing shares due October 16, 2025 (the '2025 OCEANEs'). GENFIT also announced that it intended to offer to interested bondholders to repurchase their 2025 OCEANEs. In the Royalty Financing, HCRx will be compensated and repaid out of a portion of the royalties which GENFIT is eligible to receive on sales of Iqirvo® (elafibranor) pursuant to its long-term strategic partnership with Ipsen. To secure its obligations under the Royalty Financing, GENFIT will transfer the corresponding royalty receivables to a French law trust ( fiducie-sûreté) for the benefit of the holders of the royalty financing bonds. The terms and conditions of the 2025 OCEANEs contain a negative pledge clause which limits GENFIT's ability to grant security interests to its creditors on its present or future assets or revenues. Granting the fiducie-sûreté is not permitted under this clause. The closing of the Royalty Financing (i.e. the payment of the first €130 million under the Royalty Financing) is thus conditioned upon the holders of the 2025 OCEANEs approving an amendment to the negative pledge clause (the 'Amendment of Terms'). If the Amendment of Terms is approved1, and the closing of the royalty financing is completed, GENFIT will pay a consent fee (the 'Consent Fee') to the holders of 2025 OCEANEs still outstanding after cancellation of the repurchased 2025 OCEANEs. Concurrently with the Amendment of Terms, GENFIT is proposing to repurchase the 2025 OCEANEs of any interested holder (the 'Repurchase' and, together with the Amendment of Terms, the 'Transaction'). Dual Proposal to the 2025 OCEANEs holders GENFIT and Natixis, its Solicitation Advisor, have collected feedback from the 2025 OCEANEs holders in order to set the definitive terms of the Transaction. GENFIT proposes: to repurchase 2025 OCEANEs at a price of EUR 32.00 per bond, or alternatively to pay a Consent Fee of EUR 0.60 per 2025 OCEANE In the coming days, GENFIT will propose to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally and irrevocably undertake to repurchase the 2025 OCEANEs of such holder, subject to approval by the general meeting of the 2025 OCEANEs holders of the Amendment of Terms and the closing of the Royalty Financing. After execution of the Put Option Agreement, the holder will have until several days after the closing of the Royalty Financing to exercise its option under the Agreement. Holders of the 2025 OCEANEs who have not entered into the Put Option Agreement or who do not exercise their option will receive the Consent Fee. As stated above, both the Repurchase and the payment of the Consent Fee are subject to (i) the approval by the general meeting of the 2025 OCEANEs holders of the Amendment of Terms, and (ii) the closing of the Royalty Financing. 2025 OCEANEs holders interested in the Repurchase are invited to contact (i) with respect to qualified investors, GENFIT at [email protected] or their usual sales contact at Natixis (the 'Solicitation Advisor'), or at [email protected] or at [email protected], and (ii) with respect to retail holders, the 2025 OCEANEs Bondholders Representative (Représentant de la Masse) at [email protected]. The Consent Fee will only be paid after the Repurchase has taken place. 2025 OCEANEs that have been bought back by GENFIT as part of the Repurchase (or that have been converted prior to 5:00 p.m. (Paris time) on the date falling 2 business days prior to the date of payment of the Consent Fee) will thus not receive the Consent Fee. The terms and conditions of the 2025 OCEANEs contain a clean-up call option at par if the total number of 2025 OCEANEs still outstanding represents 15% or less of the number of 2025 OCEANEs originally issued (that is 912,162 2025 OCEANEs or less, compared to 1,902,698 2025 OCEANEs outstanding as of today). GENFIT undertakes that, following the Repurchase, it will not exercise this clean-up call option until the 2025 OCEANEs reach maturity. In the coming days, GENFIT will convene a general meeting of the 2025 OCEANEs holders, which is expected to be held in early March. A Consent Solicitation Memorandum will be published, together with the documents required by French law. The results of the general meeting and the closing of the Royalty Financing will be announced in two subsequent press releases. Natixis is acting as sole solicitation advisor to assist GENFIT to seek the consent of the holders of the 2025 OCEANEs and in the repurchase of the 2025 OCEANEs. CMS Francis Lefebvre is acting as legal advisor to GENFIT. ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor2) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about the completion of the royalty financing and the timing of and the vote of the bondholders at the 2025 OCEANEs general meeting. The use of certain words, such as 'believe', 'potential', 'expect', 'target', 'may', 'will', 'should', 'could', 'if' and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 'Risk Factors and Internal Control' of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ('AMF'), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024, the Half-Year Business and Financial Report dated September 19, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors 1 The required quorum is 1/4 of the outstanding 2025 OCEANEs and the required majority is 2/3 of the 2025 OCEANEs holders present or represented. 2 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®.
